Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Audrey Simonaggio"'
Autor:
Adrien Joseph, Audrey Simonaggio, Annabelle Stoclin, Antoine Vieillard-Baron, Guillaume Geri, Stéphane Oudard, Jean-Marie Michot, Olivier Lambotte, Elie Azoulay, Virginie Lemiale
Publikováno v:
Annals of Intensive Care, Vol 10, Iss 1, Pp 1-11 (2020)
Abstract Background Immune checkpoint inhibitors have reshaped the standard of care in oncology. However, they have been associated with potentially life-threatening immune-related adverse events. With the growing indications of immune checkpoint inh
Externí odkaz:
https://doaj.org/article/f94ee5ecb92c4a2893de43b530d39bd7
Autor:
Cheng-Ming Sun, Marco Moreira, Audrey Simonaggio, Reza Elaidi, Nicolas Epaillard, Stéphane Oudard, Yann-Alexandre Vano
Publikováno v:
Bulletin du Cancer. 107:S24-S34
The standard of care for metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the past decades thanks to the increasing number of treatments: anti-VEGFR tyrosine kinase inhibitors (TKI), mTOR inhibitors and immune checkpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26df72096190c07ca6451adf30e8bdec
https://doi.org/10.1016/s0007-4551(20)30275-7
https://doi.org/10.1016/s0007-4551(20)30275-7
Autor:
Fouzia Azzouz, Audrey Simonaggio, Marco Moreira, Cheng-Ming Sun, Nicolas Epaillard, Elena Braychenko, Yann-Alexandre Vano, Stéphane Oudard, Reza Elaidi, Constance Thibault
Publikováno v:
Bulletin du Cancer. 107:eS22-eS27
Summary Background: The nivolumab-ipilimumab combination provides an overall response rate of 42% in first-line metastatic treatment of clear cell renal carcinoma (mccRCC). To date, there is no robust predictive biomarker of response to immune checkp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22ee843de9dc8fb7014739dd70ddd8b
https://doi.org/10.1016/s0007-4551(20)30283-6
https://doi.org/10.1016/s0007-4551(20)30283-6
Autor:
Zoé Guillaume, Jacques Medioni, Agnes Lillo-Lelouet, Stéphane Oudard, Audrey Simonaggio, Grégoire Marret
Publikováno v:
Clinical Breast Cancer. 20:e192-e195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abc6b4a837bf91df604f88f4d23cd1e7
https://doi.org/10.1016/j.clbc.2020.01.009
https://doi.org/10.1016/j.clbc.2020.01.009
Autor:
Yann-Alexandre Vano, Letuan Phan, Audrey Simonaggio, Mostefa Bennamoun, Diane Pannier, Christine Chevreau, Delphine Borchiellini, Denis Maillet, Marine Gross-Goupil, Brigitte Laguerre, Christophe Tournigand, Philippe Barthelemy, Elodie Coquan, Gwenaelle Gravis, Cheng-Ming Sun, Maxime Meylan, Wolf-Hervé Fridman, Catherine Sautès-Fridman, Réza Elaidi, Stephane Oudard
Publikováno v:
Journal of Clinical Oncology. 41:607-607
607 Background: To date, no biomarker of efficacy of nivolumab+/-ipilimumab (N+/-I) or anti-VEGFR TKI has been prospectively validated in mRCC. The BIONIKK trial showed promising objective response rate (ORR) and progression-free survival (PFS) with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b2545f53fedb0f5d61375c75e20f63
https://doi.org/10.1200/jco.2023.41.6_suppl.607
https://doi.org/10.1200/jco.2023.41.6_suppl.607
Autor:
Audrey Simonaggio, Damien Ambrosetti, Virginie Verkarre, Marie Auvray, Stéphane Oudard, Yann-Alexandre Vano
Publikováno v:
International Journal of Molecular Sciences. 23:7649
MiTF/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC representing the most prevalent RCC in the pediatric population (up to 40%) and making up 4% of all RCCs in adults. It is characterized by translocations invol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e8707a8284778234725020bfb324bc
https://doi.org/10.3390/ijms23147649
https://doi.org/10.3390/ijms23147649
Autor:
Jean-Emmanuel Bibault, Adrien Procureur, Stéphane Oudard, Yann-Alexandre Vano, Audrey Simonaggio
Publikováno v:
Cancers, Vol 13, Iss 678, p 678 (2021)
Cancers
Cancers, MDPI, 2021, 13 (4), pp.678. ⟨10.3390/cancers13040678⟩
Cancers
Cancers, MDPI, 2021, 13 (4), pp.678. ⟨10.3390/cancers13040678⟩
Simple Summary Efficient antitumoral immune response is conditioned by a regulated cell death called immunogenic cell death. Many immunologic cell death inducers are currently used in cancer treatment. Among them, radiation therapy is an adaptable, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341041d1e030af97ac7daad6ae33da44
https://www.mdpi.com/2072-6694/13/4/678
https://www.mdpi.com/2072-6694/13/4/678
Autor:
Nicolas Delanoy, Edouard Auclin, Yann-Alexandre Vano, Audrey Simonaggio, Alice Clément-Zhao, Cedric Pobel, Stéphane Oudard, Adrien Procureur, Constance Thibault
Publikováno v:
Future oncology (London, England). 17(1)
Cabazitaxel (25 mg/m2 every 3 weeks) is the standard second-line chemotherapy for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. It is associated with a risk of neutropenic complications, which may be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7ef20982ac49318bc560fe7b0ec0ff
https://pubmed.ncbi.nlm.nih.gov/33463373
https://pubmed.ncbi.nlm.nih.gov/33463373
Autor:
Arthur Daban, Cecile Gonnin, Yann-Alexandre Vano, Letuan Phan, Agnes lillo-Lelouet, Christine le Beller, Jacques Pouchot, Elizabeth Fabre, Laurence Weiss, Eric Tartour, Stephane Oudard, Marie-Agnès Dragon Durey, Audrey Simonaggio
Publikováno v:
Journal of Clinical Oncology. 40:2523-2523
2523 Background: Immune checkpoint inhibitors (ICIs), used alone or as a combination are standard of care in many cancers. Generally well tolerated, they can generate immune-related adverse events (irAEs). No biomarkers are available to identify pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f673ba6513e67c610aa7a586472a22f1
https://doi.org/10.1200/jco.2022.40.16_suppl.2523
https://doi.org/10.1200/jco.2022.40.16_suppl.2523
Autor:
Audrey, Simonaggio, Marie, Auvray-Kuentz, Adrien, Rochand, Constance, Thibault, Claire, Gervais, Stéphane, Oudard, Yann-Alexandre, Vano
Publikováno v:
Bulletin du Cancer. 109:2S47-2S58
The field of clear cell renal cell carcinoma (ccRCC) has undergone major changes in the last decade, both in terms of the understanding of the mechanisms of oncogenesis and the role of the tumor microenvironment in anti-tumor immunity, as well as in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e96ef5fb8241a5c78da9be35ef69eb77
https://doi.org/10.1016/s0007-4551(22)00238-7
https://doi.org/10.1016/s0007-4551(22)00238-7